首页|基于PI3K-AKT-mTOR通路探讨泽曲明山复方对大鼠非酒精性脂肪性肝炎模型的影响

基于PI3K-AKT-mTOR通路探讨泽曲明山复方对大鼠非酒精性脂肪性肝炎模型的影响

扫码查看
目的 泽曲明山复方是临床治疗代谢相关性脂肪性肝病(MAFLD)的经验方。研究探讨该经验方对大鼠非酒精性脂肪性肝炎(NASH)模型的影响以及可能的机制。方法 Sprague-Dawley大鼠给予胆碱缺乏高脂饲料(CDHF diet)8周建立NASH模型。随机分为模型组,中药低、高剂量组以及水林佳组;建立模型同时给予对应药物干预。给予胆碱充足高脂饲料(CSHF diet)作为对照组。观察相应药物对模型大鼠血清生化学、肝脏病理、磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(PKB/AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)通路信号转导通路mRNA、蛋白表达的影响。结果 (1)体质量以及肝脏/体质量:5组大鼠体质量差异无统计学意义,模型组大鼠肝脏/体质量显著升高,各干预组大鼠肝脏/体质量不同程度下降,中药高剂量组疗效最为明显。(2)肝功能以及血脂:与对照组相比,模型组大鼠血清肝功能及血脂水平显著升高;各干预组大鼠肝功能以及血脂不同程度降低,其中中药高剂量组疗效最为明显。(3)肝脏病理:模型组大鼠肝脏HE染色可见胞浆内大量脂肪空泡以及炎性细胞浸润;Sirius red染色可见中央静脉大量纤维组织沉积,证实模型成立;各干预组肝脏HE以及Sirius red染色均有不同程度改善,中药高剂量组改善最为明显。(4)对肝组织固醇调节元件结合蛋白1(SREBP-1)、低密度脂蛋白受体(LDLR)mRNA表达的影响:与对照组相比,模型组SREBP-1 mRNA表达明显升高;各干预组有不同程度下调,其中中药高剂量组最为明显。与对照组相比,模型组大鼠LDLR mRNA表达明显下降;各干预组表达有不同程度增加,其中中药高剂量组改善最为明显。(5)对肝组织SREBP-1、LDLR蛋白表达的影响:与对照组相比,模型组大鼠肝组织中SREBP-1蛋白染色深,各干预组较模型组染色浅,其中中药组效果更显著。与对照组相比,模型组大鼠肝组织中LDLR蛋白染色浅,各干预组较模型组染色深,其中中药高剂量组效果更显著。(6)对肝组织磷脂酰肌醇3-激酶(PI3K)、雷帕霉素靶蛋白(mTOR)、蛋白激酶B(PKB/AKT)蛋白表达的影响:通过免疫荧光染色观察,模型组样本细胞的荧光信号表达明亮且分布不均匀;对照组荧光信号表达暗淡;各干预组较模型组荧光信号表达亮度下调,中药干预组改善更明显。结论 泽曲明山复方可能通过调控PI3K/AKT/mTOR通路,起到减轻肝脏炎症反应、减少肝内脂肪生成和聚集,改善NASH的目的,并在治疗过程中表现出剂量相关性。
Effect of Zequ Mingshan Compound Prescription(泽曲明山复方)on Mouse Model of Non-alcoholic Steatohepatitis
Objective Zequ Mingshan Compound Prescription(泽曲明山复方)is an empirical formula for the clinical treat-ment of metabolic associated fatty liver disease(MAFLD).This study explored the impact of this empirical formula on the rat model of non-alcoholic steatohepatitis(NASH)and its possible mechanisms.Method SD rats were given choline deficient high fat diet(CDHF diet)for 8 weeks to establish a NASH model.The rats were randomly divided into model group,low and high dose groups of traditional Chinese medicine and Shuilinjia group.The model was established and the corresponding drug interven-tion was provided.The choline rich high fat diet(CSHF diet)was as the control group.The effects of corresponding drugs on ser-um biochemistry,liver pathology,PI3 K-AKT-mTOR signaling pathway mRNA and protein expression in model rats were com-pared.Results(1)Body weight and liver/body weight:There was no statistically significant difference in body weight among the 5 groups.The liver/body weight of the rats of the model group significantly increased,while the liver/body weight of the rats of each intervention group decreased to varying degrees.The high-dose group had the most significant therapeutic effect.(2)Liver function and blood lipids:Compared with those of the control group,the serum levels of alaninetransaminase(ALT),glutamic oxa-loacetic transaminase(AST),triglyceride(TG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)of the model group were significantly increased.The liver function and blood lipids of rats in each intervention group decreased to var-ying degrees,with the high-dose group having the most significant therapeutic effect.(3)Liver pathology:HE staining showed a large number of fat vacuoles and inflammatory cell infiltration in the cytoplasm of the liver of the model group rats.Sirius red stai-ning showed a large amount of fibrous tissue deposition in the central vein,confirming the validity of the model.Each intervention group showed varying degrees of improvement in liver HE and Sirius red staining,with the high-dose group showing the most sig-nificant improvement.(4)Effect on the mRNA expressions of SREBP-1 and LDLR in liver tissue:Compared with the control group,the model group showed a significant increase in SREBP-1 mRNA expression.Each intervention group showed varying degrees of down-regulation,with the high-dose group being the most significant.Compared with those in the control group,the expression of LDLR mRNA in the model group decreased significantly.The expression levels increased to varying degrees in each intervention group,with the high-dose group showing the most significant improvement.(5)Effect on the expressions of SREBP-1 and LDLR proteins in liver tissue:Compared with those of the control group,the SREBP-1 protein staining in the liv-er tissue of the model group rats was deeper,and the staining in each intervention group was lighter than that in the model group.Among them,the effect of the traditional Chinese medicine group was more significant.Compared with that of the control group,the LDLR protein staining in the liver tissue of the model group was shallow,while the staining in each intervention group was deeper than that in the model group.Among them,the high-dose group had a more significant effect.(6)The effect on the ex-pressions of PI3K,mTOR and AKT proteins in liver tissue:Through immunofluorescence staining observation,the fluorescence signal expression of the sample cells in the model group was bright and unevenly distributed.The fluorescence signal expression in the control group was dim.The fluorescence signal expression brightness of each intervention group was down-regulated com-pared to that of the model group and the improvement was more significant in the traditional Chinese medicine intervention group.Conclusion Zequ Mingshan Compound Prescription may alleviate liver inflammation,reduce hepatic production and accumula-tion,improve NASH by regulating the PI3 K/AKT/mTOR pathway and exhibit dose-dependent effects during treatment.

Zequ Mingshan Compound Prescription(泽曲明山复方)non alcoholic steatohepatitisPI3K-AKT-mTOR pathway

郑佳连、张艳、卢秉久、张红、韩永辉、付博

展开 >

辽宁中医药大学,辽宁沈阳 110847

辽宁中医药大学附属医院,沈阳辽宁 110032

鞍山市精神卫生中心,辽宁鞍山 114001

沈阳市第六人民医院,辽宁沈阳 110006

展开 >

泽曲明山复方 非酒精性脂肪性肝炎 PI3K-AKT-mTOR通路

2024

中华中医药学刊
中华中医药学会 ,辽宁中医药大学

中华中医药学刊

CSTPCD北大核心
影响因子:1.007
ISSN:1673-7717
年,卷(期):2024.42(12)